Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue

Related MYL
Top Takeaways From BMO's Specialty Pharma Day
Top Performing Industries For June 16, 2015
Medicines Co., Eagle Pharma Up On Analyst Actions (Investor's Business Daily)
Related SLXP
Benzinga's Volume Movers
US Stock Futures Edge Lower Ahead Of ADP Report
Sector's Smaller Players Show The Way (Seeking Alpha)

Below are the top drugs-generic stocks on the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Mylan (NASDAQ: MYL) is $6.39 billion. Mylan's ROA for the same period is 5.89%.

The trailing-twelve-month revenue at Salix Pharmaceuticals Ltd (NASDAQ: SLXP) is $605.72 million. Salix Pharmaceuticals had $665.87 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Hi Tech Pharmacal Co (NASDAQ: HITK) is $230.00 million. Hi Tech Pharmacal's ROE for the same period is 23.17%.

The trailing-twelve-month revenue at Akorn (NASDAQ: AKRX) is $163.19 million. Akorn's operating margin for the same period is 26.68%.

Posted-In: Drugs-Generic Industry Highest Revenue NASDAQTrading Ideas


Related Articles (AKRX + HITK)

Around the Web, We're Loving...

Get Benzinga's Newsletters